




Conjunctival Melanoma Fact Sheet

Cancer Type: Ocular Surface Cancer

Primary Site: Conjunctiva (membrane covering the white of the eye and inside of eyelids)

Rarity: Very Rare (less than 2% of all eye tumors)

Source: [OcularCancer.com](https://www.ocularcancer.com)

What is Conjunctival Melanoma?

Conjunctival melanoma is a rare and potentially life-threatening cancer that originates in the **melanocytes** (pigment-producing cells) of the conjunctiva. It appears as a darkly pigmented or sometimes pink lesion on the surface of the eye and can spread locally or metastasize (spread to other parts of the body).

Key Facts:

- **Prevalence:** ~0.2 to 0.5 cases per million people annually
 - **Typical Age at Diagnosis:** 50 - 70 years old
 - **Gender:** Affects both men and women equally
 - **Laterality:** Usually affects one eye (unilateral)
-

Causes & Risk Factors:

- **Primary acquired melanosis (PAM)** with atypia (pre-cancerous condition)
 - Pre-existing **nevus** (eye mole)
 - UV radiation exposure (possible risk factor)
 - Fair skin and light-colored eyes
 - Genetic mutations (e.g., **BRAF**, **NRAS**, **TERT** promoter mutations)
-

Signs and Symptoms:

- Pigmented (dark brown, black) or non-pigmented (pink, flesh-colored) lesion on the eye
 - Lesion may be **raised**, **vascularized**, or **mobile**
 - Growth or change in a pigmented spot on the conjunctiva
 - Redness, irritation, or foreign body sensation (sometimes)
 - Possible spread to local lymph nodes
-

Diagnosis:

- **Slit-lamp examination** by an ophthalmologist
 - **Photographic monitoring** of lesions over time
 - **Biopsy** (excisional or incisional) to confirm malignancy
 - **Immunohistochemistry & genetic testing** for mutation profiling
 - **Imaging** (MRI, CT, ultrasound) to check for orbital or systemic spread
 - **Sentinel lymph node biopsy** in some cases
-

Staging & Spread:

- **Local invasion:** Can extend onto the cornea, sclera, or eyelids
 - **Lymphatic spread:** Regional lymph nodes (parotid, submandibular, cervical)
 - **Distant metastasis:** Lungs, liver, brain (rare but possible)
-

Treatment Options:

- **Surgical excision** with clear margins
 - **“No-touch” surgical technique** to prevent cell seeding
 - **Cryotherapy** to edges after removal
 - **Topical chemotherapy** (e.g., Mitomycin C)
 - **Radiation therapy** (plaque brachytherapy or proton beam in advanced cases)
 - **Lymph node dissection** if nodal involvement
 - **Systemic immunotherapy or targeted therapy** (in metastatic or advanced cases)
-

Prognosis:

- **5-year survival rate:** ~80 - 90% with early diagnosis and treatment
 - **Local recurrence:** Up to 50% (close follow-up essential)
 - **Metastasis risk:** ~15 - 25% in long-term follow-up
 - **Best outcomes** with early detection and complete surgical removal
-

Follow-Up & Monitoring:

- Frequent eye exams every 3 - 6 months initially, then annually
 - Long-term monitoring for recurrence or metastasis
 - Imaging of lymph nodes and distant organs as needed
-

Support & Resources:

- Genetic counseling for mutation-positive patients
 - Ocular oncology and surgical specialists
 - Survivor networks and rare cancer support groups
 - Eye prosthetics (if extensive surgery is needed)
-

Key Takeaways:

- **Early detection is critical** - monitor pigmented or growing eye lesions
 - High recurrence risk demands **regular, long-term follow-up**
 - Advanced therapies now offer improved outcomes even in complex cases
 - **Conjunctival melanoma is rare but treatable** when caught early
-

 **For more information, patient stories, and support, visit:**

 [OcularCancer.com](https://ocularcancer.com) - Your resource for education, awareness, and connection for rare eye cancers.